Centene thalidomide coverage & Prior Auth

Coverage and Medical Necessity Criteria

Initial Therapy: Multiple Myeloma

Initial Approval Criteria - Multiple Myeloma (must meet ALL):

MM initial criteria: 1) Diagnosis of multiple myeloma; 2) Prescribed by or in consultation with an oncologist or hematologist; 3) Age >= 12 years; 4) Prescribed in combination with dexamethasone; 5) Thalomid is not prescribed concurrently with lenalidomide or pomalidomide; 6) Member must use generic thalidomide if available unless contraindicated or clinically significant adverse effects are experienced; 7) Dose does not exceed both of the following: i) 200 mg per day and ii) 1 capsule per day, OR b) dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence); 8) Prescribed regimen must be FDA-approved or recommended by NCCN.dose limits: 200 mg/day; 1 capsule/day

Approval duration: 6 months

Initial Therapy: ENL

Initial Approval Criteria - Erythema Nodosum Leprosum (must meet ALL):

ENL initial criteria: 1) Diagnosis of erythema nodosum leprosum (ENL); 2) Prescribed by or in consultation with an infectious disease specialist, immunologist, or dermatologist; 3) Age >= 12 years; 4) Thalomid is not prescribed concurrently with lenalidomide or pomalidomide; 5) Member must use generic thalidomide if available unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed both of the following: a) 400 mg per day and b) 2 capsules per day.dose limits: 400 mg/day; 2 capsules/day

Approval duration: 6 months

Initial Therapy: NCCN Compendium (off‑label)

Initial Approval Criteria - NCCN Compendium Indications (off‑label) (must meet ALL):

NCCN compendium criteria: 1) Diagnosis of an included NCCN compendium indication (examples: multicentric Castleman disease [MCD], Kaposi sarcoma, pediatric medulloblastoma, Langerhans cell histiocytosis or Rosai‑Dorfman disease); 2) Prescribed by or in consultation with the relevant specialist (oncologist, hematologist, immunologist, or other specialist as specified for the indication); 3) Age >= 12 years where specified; 4) For MCD: active idiopathic MCD without organ failure, HHV‑8 negative, HIV negative, and prescribed in combination with cyclophosphamide and prednisone; 5) For Kaposi sarcoma: subsequent therapy after progression following prior agents or, if AIDS‑related, prescribed in combination with antiretroviral therapy; failure of liposomal doxorubicin and paclitaxel unless contraindicated; 6) For Langerhans cell histiocytosis or Rosai‑Dorfman disease: single‑agent use; 7) For pediatric medulloblastoma: prescribed as part of the MEMMAT regimen; 8) Thalomid is not prescribed concurrently with lenalidomide or pomalidomide; 9) Member must use generic thalidomide if available unless contraindicated or clinically significant adverse effects are experienced; 10) Dose does not exceed both of the following: i) 400 mg per day and ii) 2 capsules per day, OR b) dose is supported by practice guidelines or peer‑reviewed literature for the relevant off‑label use (prescriber must submit supporting evidence); 11) Prescribed regimen must be FDA‑approved or recommended by NCCN.dose limits often 400 mg/day; 2 capsules/day

Approval duration: 6 months

Initial Therapy: Aphthous Stomatitis/Ulcers

Initial Approval Criteria - Aphthous Stomatitis or Ulcers (off‑label) (must meet ALL):

Aphthous ulcers criteria: 1) Diagnosis of HIV‑associated aphthous ulcers or aphthous stomatitis in immunocompetent members; 2) Age > 12 years; 3) Failure of a systemic corticosteroid unless clinically significant adverse effects are experienced or corticosteroids are contraindicated; 4) Thalomid is not prescribed concurrently with lenalidomide or pomalidomide; 5) Member must use generic thalidomide if available unless contraindicated or clinically significant adverse effects are experienced; 6) Dose does not exceed both of the following: i) 400 mg per day and ii) 2 capsules per day, OR b) dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).400 mg/day; 2 capsules/day

Approval duration: 6 months; Illinois HIM exception for step therapy noted

Continued Therapy

Continued Therapy (must meet ONE of following):

Continued therapy criteria: a) Member currently receiving medication via Centene benefit or member has previously met initial approval criteria; b) Documentation supports member is currently receiving Thalomid for oncology and has received it for at least 30 days; c) Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (refer to state addendums); PLUS all of the following: member is responding positively to therapy; Thalomid is not prescribed concurrently with lenalidomide or pomalidomide; member must use generic thalidomide if available unless contraindicated or clinically significant adverse effects are experienced; if request is for a dose increase, new dose must meet limits: for MM the new dose does not exceed 200 mg/day or 1 capsule/day as specified, and for all other indications does not exceed 400 mg/day or 2 capsules/day, OR the new dose is supported by practice guidelines or peer‑reviewed literature (prescriber must submit supporting evidence).Dose increase limits: MM up to 200 mg/day (or 1 capsule/day), others up to 400 mg/day (or 1-2 capsules/day) if supported

Approval duration: 12 months

Coverage is not authorized for non‑FDA‑approved indications that are not specifically addressed in this policy unless the provider submits sufficient clinical documentation demonstrating efficacy and safety in accordance with applicable off‑label use policies (for example, CPCPA.09 for commercial, HIM.PA.154 for Health Insurance Marketplace, or CP PMN.53 for Medicaid) or unless the member’s evidence of coverage document permits the use.

Concurrent prescription of thalidomide with the thalidomide‑analog agents lenalidomide (Revlimid) or pomalidomide (Pomalyst) is not permitted under this policy and will render the request ineligible for coverage.

Initial Therapy by Indication

Initial therapy

Initial therapy coverage criteria are grouped by indication below. See each indication-specific criteria set for detailed requirements.

Grouped initial therapy by indication: Multiple myeloma; Erythema nodosum leprosum (ENL); NCCN Compendium indications (off‑label) such as MCD, Kaposi sarcoma, pediatric medulloblastoma, LCH/Rosai‑Dorfman; Aphthous stomatitis/ulcers (off‑label). For each indication, requests must meet the indication-specific requirements for diagnosis, prescriber specialty, age, non‑concurrent use with lenalidomide/pomalidomide, use of generic if available unless contraindicated, dosing within policy limits or supported by guidelines/literature, and that the prescribed regimen is FDA‑approved or NCCN‑recommended.

Initial therapy (historical)

Historical notes on initial therapy criteria and approval durations:

Historical initial therapy notes: Approval durations were consolidated historically to 6 months for initial therapy. Over time the policy added and revised off‑label indications (including aphthous stomatitis/ulcers and various NCCN compendium indications), and updated specialist and dosing requirements to align with NCCN and clinical references.

Continuation / Renewal Requirements

Continuation

Continued therapy operational requirements for renewal:

Continuation operational criteria: See Continued Therapy criteria: member must meet one of the continuation conditions (current Centene benefit with prior initial approval; oncology patient on therapy >=30 days; or enrolled in state/product continuity of care) AND member must be responding positively to therapy; Thalomid must not be prescribed concurrently with lenalidomide or pomalidomide; generic thalidomide must be used if available unless contraindicated; dose increases require meeting the policy dose limits or submission of supporting guidelines/literature; prescribed regimen must be FDA‑approved or NCCN‑recommended where applicable.

Approval duration for continuation: 12 months

Continuation therapy (historical)

Historical continuation notes and continuity of care rules:

Continuation historical notes: Continuation approval duration was consolidated historically to 12 months. Continuity of care provisions were clarified: continuity of care applies to oncologic indications but does not apply to ENL, aphthous stomatitis, or aphthous ulcers. Prior revisions added the restriction prohibiting concurrent use with lenalidomide or pomalidomide and refined generic redirection language.

Dose Limits and Coding-related Values

Maximum dose thresholds — inv-08: Maximum dose thresholds

Multiple Myeloma (MM) — maximum daily doseDoes not exceed both: i) 200 mg per day and ii) 1 capsule per day

Erythema Nodosum Leprosum (ENL) — maximum daily doseDoes not exceed both: a) 400 mg per day and b) 2 capsules per day (typical dosing 100–300 mg PO QD)

Other indications (including NCCN/off‑label and aphthous stomatitis) — maximum daily doseNew dose does not exceed 400 mg per day and 2 capsules per day OR is supported by practice guidelines/peer‑reviewed literature with submitted evidence

Dose‑increase rule for MM on continuationIf request is for a dose increase for MM, new dose must not exceed 200 mg/day (or 1 capsule/day) unless supported by literature/guidelines

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for Thalomid (thalidomide). Providers must obtain prior authorization before initiating therapy.

Prescriber specialty/consultation: Many indications require the drug to be prescribed by or in consultation with a relevant specialist (e.g., oncologist or hematologist for multiple myeloma; infectious disease specialist, immunologist, or dermatologist for erythema nodosum leprosum; see indication-specific criteria).
Dosing limits: Requests must meet the policy's dose limits (examples: ≤200 mg/day and ≤1 capsule/day for some indications; ≤400 mg/day and ≤2 capsules/day for others) or be supported by practice guidelines or peer-reviewed literature with supporting evidence submitted by the prescriber.
Operational requirements: Prior authorization requests must follow plan-specific processes and may be subject to generic redirection (member must use generic thalidomide if available unless contraindicated).
Concurrent therapy restriction: Thalidomide must NOT be prescribed concurrently with lenalidomide (Revlimid) or pomalidomide (Pomalyst) — concurrent use with these thalidomide-analogs is not allowed.

Prior Authorization

Prior Authorization and Approval Durations

Abbreviations and Definitions

inv-19: ENL — abbreviation definition

ENLErythema nodosum leprosum

ContextListed in the policy Appendix A abbreviation/acronym key as 'ENL: erythema nodosum leprosum'

Typical useReferenced as an indication historically covered under the policy for treatment and maintenance related to ENL

inv-20: MM — abbreviation definition

MMMultiple myeloma

Context in policyDefined in Appendix A abbreviation key and used throughout initial and continuation criteria (e.g., MM dosing limit 200 mg/day)

Typical regimen note

Step Therapy and Statutory Overrides

Requirement	Applies / Notes
Step therapy requirement applies generally for thalidomide requests
Illinois HIM exception: For aphthous stomatitis or ulcers, step therapy requirements do not apply in Illinois HIM effective 1/1/2026 per IL HB 5395

Revision note	Effect on therapy
Policy revision entry documents statutory change per IL HB 5395 (noted in policy history) adding a therapy bypass for aphthous stomatitis/ulcers
Therapy bypass implemented for aphthous stomatitis or ulcers in Illinois HIM (therapy bypass referenced as added in policy revisions per IL HB 5395)

Background and Product Information

Thalidomide is an immunomodulatory agent with FDA approvals for use in multiple myeloma (in combination with dexamethasone) and for the treatment and maintenance of cutaneous manifestations of erythema nodosum leprosum (ENL). The medication carries serious safety warnings, including embryo‑fetal toxicity that requires patient and prescriber enrollment in the Thalomid REMS restricted distribution program, and an increased risk of venous thromboembolism. Dosing recommendations and maximum daily limits vary by indication and are specified elsewhere in this policy.

OpenPayer

Thalidomide (Thalomid) coverage

Coverage and Medical Necessity Criteria

Initial Therapy by Indication

Continuation / Renewal Requirements

Dose Limits and Coding-related Values

Prior Authorization, Documentation, and Provider Requirements

Abbreviations and Definitions

Step Therapy and Statutory Overrides

Background and Product Information